
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Pharmaceutical Science & Technology Innovations
almost 22 years ago
A Novel Freeze Pelletization Technique for Preparing Matix Pelletsalmost 22 years ago
Aseptic Processing: A Review of Current Industry Practicealmost 22 years ago
Can Inserts Be Improved?almost 22 years ago
Drug Development Linked More Closely to Diagnosticsalmost 22 years ago
October 2004almost 22 years ago
The High Price of Successalmost 22 years ago
Pharma Company Investment in Parenteral Manufacturing Capacity Picking Up





